Biotech Business Advises on Preclinical Collaboration to Evaluate Potential Novel Vaccine Adjuvants

Biotech Business Advises on Preclinical Collaboration to Evaluate Potential Novel Vaccine Adjuvants

December - 2018

Biotech Business recently advised one of our clients on a preclinical collaboration with the National Institute of Biological Standards and Controls in the UK. The collaboration will evaluate the activity of novel immunomodulatory molecules as potential adjuvants for use in combination with vaccines against certain bacterial infections. Further details are confidential.

Comments are closed.